SurModics (SRDX) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/22/2026
- S&P 500 is close to flat as investors await technology earnings
- Oil climbs more than 2% to multi-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
- Foreign buying surge may signal trouble ahead for the S&P 500
- AMD challenges Nvidia with massive Anthropic deal, though shares dip pre-market
- Emirates refusing to take delivery of first 10 Boeing 777X jets
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- Crude Inventory Rose 2 Million Barrels Last Week - EIA
- Wall St ends higher on chip stocks recovery; earnings in focus
- Palo Alto Networks to acquire Embrace to expand observability tools
Surmodics Reports Third Quarter Fiscal 2021 Results and Updates Fiscal 2021 Revenue and EPS Guidance
August 4, 2021 7:30 AM EDTEDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 third quarter ended June 30, 2021 and updated its financial outlook for its fiscal 2021.
Summary of Third Quarter and Recent Highlights
Revenue of $23.9 million, a decrease of 11% year-over-year GAAP EPS of $(0.24), non-GAAP EPS of $(0.17) PMA submission completed for SurVeil drug-coated balloon FDA 510(k) clearance received for Sublime .018 RX PTA Dilatation Catheter Successful first patient... More